Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

The psychedelic ibogaine may be useful for psychiatric disorders, including addiction

Staff Writer
Staff Writer 2 years ago
Updated 2021/10/23 at 2:11 PM
Share
SHARE

The psychedelic drug known as ibogaine may be useful for treating several psychiatric disorders, including addiction, new research in the journal Nature concluded.

Derived from the plant Tabernanthe iboga, a team at UC Davis set out to experiment on the ibogaine drug but without administering its psychedelic compound, which may be undesirable as a therapeutic treatment.

The study led to the creation of a new synthetic, water-soluble molecule called tabernanthalog.

“Here we apply the principles of function-oriented synthesis to identify the key structural elements of the potential therapeutic pharmacophore of ibogaine, and we use this information to engineer tabernanthalog—a water-soluble, non-hallucinogenic, non-toxic analogue of ibogaine that can be prepared in a single step,” the study says.


Researchers utilized rodents to experiment with tabernanthalog and established its impact on structural neural plasticity, enabling its use for therapeutic means.

Tabernanthalog, overall, was shown to reduce addiction-like behavior among the rodents, as well as producing antidepressant-like effects deemed to be of significant therapeutic potential.

“In rodents, tabernanthalog was found to promote structural neural plasticity, reduce alcohol- and heroin-seeking behaviour, and produce antidepressant-like effects,” the co-authors wrote in their Nature article.

“This work demonstrates that, through careful chemical design, it is possible to modify a psychedelic compound to produce a safer, non-hallucinogenic variant that has therapeutic potential.”

Photo: stuart elmes

You Might Also Like

New study explores test that can detect Alzheimer’s years before diagnosis

Prenatal exposure to pollution may be linked to lower cognitive scores in infants

Researchers unveil new drug candidate to help treat adrenoleukodystrophy

New research finds Alzheimer’s risk factors affect males and females very differently

Study establishes critical role in regulating excessive folding of gyri in brain

TAGGED: ibogaine, mental health, psychodelics, drugs
Staff Writer December 9, 2020
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Oxford’s COVID-19 vaccine is nearly half as effective as Pfizer’s vaccine
Next Article Consuming asthma medicines during pregnancy may raise the risk of premature births and small birth weight

Recommended

Clinical

New study explores test that can detect Alzheimer’s years before diagnosis

1 Min Read
Clinical

Prenatal exposure to pollution may be linked to lower cognitive scores in infants

1 Min Read
Clinical

Researchers unveil new drug candidate to help treat adrenoleukodystrophy

1 Min Read
Clinical

New research finds Alzheimer’s risk factors affect males and females very differently

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?